Your AI-Trained Oncology Knowledge Connection!
The results of the phase 3 LUNAR trial evaluating tumor treating fields plus standard-of-care therapies among patients with metastatic non–small cell lung cancer are “encouraging,” according to an expert from Winship Cancer Institute of Emory University.
Adding pembrolizumab to chemotherapy shows little increase in adverse effects among patients with metastatic nonsquamous non–small cell lung cancer in the phase 3 KEYNOTE-789 trial.
Sunvozertinib shows a similar safety profile to other EGFR tyrosine kinase inhibitors in the treatment of EGFR wild-type non–small cell lung cancer in the WO-KONH6 study.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Datopotamab deruxtecan plus pembrolizumab produces no new safety signals in the treatment of patients with advanced non–small cell lung cancer in the phase 1b TROPION-Lung02 trial.
The FDA accepts a supplemental biologics license application for dostarlimab plus chemotherapy in the treatment of mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer based on data from a prespecified interim analysis of the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial.
Avutometinib plus defactinib produces no new safety signals among those with low-grade serous ovarian cancer in the phase 2 RAMP 201 trial.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
The antitumor activity of niraparib maintenance therapy in patients with advanced ovarian cancer remains unclear among those with measurable residual disease at baseline in the phase 3 PRIME study.
Maintenance with niraparib also produces benefits in chemotherapy-free interval and time to first and second therapy among those with BRCA wild-type recurrent ovarian cancer in the phase 3 NOVA study.
Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.
The safety of fianlimab plus cemiplimab appears consistent with the safety profile previously observed with each individual agent among patients with previously treated metastatic melanoma in a phase 1 study.
Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.
Axicabtagene ciloleucel produces a higher median overall survival vs high-dose therapy plus autologous stem cell transplant among patients with relapsed or refractory large B-cell lymphoma in the phase 3 ZUMA-7 trial.
Treatment with eftilagimod alpha in combination with pembrolizumab appears safe and well tolerated among patients with metastatic head and neck squamous cell carcinoma in the phase 2 TACTI-002 study.
Pembrolizumab plus axitinib also improves the overall response rate vs sunitinib alone among patients with clear cell renal cell carcinoma in the phase 3 KEYNOTE-426 trial.
Data from the phase 3 CONTACT-03 trial highlight the necessity of randomized, prospective assessment of re-challenge with checkpoint inhibitors in renal cell carcinoma, according to an expert from Dana-Farber Cancer Institute.
Investigators report no deaths related to treatment with ABBV-011 among patients with small cell lung cancer in a first-in-human phase 1 trial.
Ciltacabtagene autoleucel may become a new standard of care for patients with lenalidomide-refractory myeloma after first relapse, according to an expert from the Medical College of Wisconsin in Milwaukee.
The anti-tumor activity of lasofoxifene plus abemaciclib does not appear to be compromised by co-occurring alterations that confer resistance among patients with estrogen receptor–positive HER2-negative breast cancer.
Fruquintinib plus best supportive care elicits a progression-free survival benefit across all prior treatment subgroups among patients with refractory metastatic colorectal cancer in the phase 3 FRESCO-2 trial.
Most adverse effects in a phase 2 trial related to doxorubicin appear to be expected in the treatment of patients with soft tissue sarcoma.
Pembrolizumab in combination with enfortumab vedotin-ejfv demonstrates a manageable safety profile in the treatment of metastatic urothelial carcinoma in the EV-103 trial.
Additionally, treatment with sacituzumab govitecan-hziy may result in a prolonged overall response rate and clinical benefit rate vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.
With no standard treatment available, darolutamide shows potential activity among patients with androgen receptor–positive salivary gland cancer in the phase 2 DISCOVARY trial.
Among patients with colorectal cancer who are ineligible for intensive chemotherapy, trifluridine/tipiracil plus bevacizumab yielded similar survival outcomes compared with capecitabine plus bevacizumab.
Lenvatinib plus pembrolizumab generates no new safety signals among patients with advanced renal cell carcinoma in the phase 3 CLEAR study.
Treatment with patritumab deruxtecan appears to yield improved responses in patients who have been heavily pretreated for metastatic breast cancer.
Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.
Common treatment-emergent adverse effects among patients receiving PRT811 for uveal melanoma or advanced glioma include nausea and vomiting in a phase 1 study.
